Back to Directory

AMR Bio

XF-73 antimicrobial advancing towards Phase 3 infection prevention

AMR Bio is a clinical-stage biotechnology company developing the XF-73 antimicrobial platform for preventing hospital-acquired infections.

Its lead nasal formulation aims to reduce Staphylococcus aureus carriage before surgery. Following Phase 2b clinical testing, the programme is preparing for Phase 3 development.

Established in 2025, AMR Bio acquired selected XF-73 intellectual property and clinical assets from Destiny Pharma during its liquidation. The US FDA confirmed transfer of the associated regulatory dossier and designations in June 2026.

Company Notes

Previously Known As
Destiny Pharma AMR Ltd